Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Cited by (439)

Items 201–300 of 439

1. Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors
   Nomura, Motoo, Nagatomo, Ryosuke, Doi, Keitaro, Shimizu, Juko, Baba, Kiichiro, Saito, Tomoki, Matsumoto, Shigemi, Inoue, Koichi, Muto, Manabu · 2020 · JAMA Network Open
2. Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family
   Bour‐Jordan, Hélène, Esensten, Jonathan H., Martinez‐Llordella, Marc, Penaranda, Cristina, Stumpf, Melanie, Bluestone, Jeffrey A. · 2011 · Immunological Reviews
3. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)
   Mitchell, Tara C., Hamid, Omid, Smith, David C., Bauer, Todd M., Wasser, Jeffrey S., Olszanski, Anthony J., Luke, Jason J., Balmanoukian, Ani S., Schmidt, Emmett V., Zhao, Yufan et al. · 2018 · Journal of Clinical Oncology
4. Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
   Cha, Edward, Klinger, Mark, Hou, Yafei, Cummings, Craig, Ribas, Antoni, Faham, Malek, Fong, Lawrence · 2014 · Science Translational Medicine
5. Translating p53 into the clinic
   Cheok, Chit Fang, Verma, Chandra S., Baselga, José, Lane, David P. · 2011 · Nature Reviews Clinical Oncology
6. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
   Goswami, Sangeeta, Walle, Thomas, Cornish, Andrew E., Basu, Sreyashi, Anandhan, Swetha, Fernandez, Irina, Vence, Luis, Blando, Jorge, Zhao, Hao, Yadav, Shalini Singh et al. · 2020 · Nature Medicine
7. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
   Sharma, Anu, Subudhi, Sumit K., Blando, Jorge, Scutti, Jorge, Vence, Luis, Wargo, Jennifer, Allison, James P., Ribas, Antoni, Sharma, Padmanee · 2019 · Clinical Cancer Research
8. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
   de Filette, Jeroen, Andreescu, Corina, Cools, Filip, Bravenboer, Bert, Velkeniers, Brigitte · 2019 · Hormone and Metabolic Research
9. Mechanisms regulating T-cell infiltration and activity in solid tumors
   Lanitis, E., Dangaj, D., Irving, M., Coukos, G. · 2017 · Annals of Oncology
10. Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
    Gebhardt, Christoffer, Sevko, Alexandra, Jiang, Huanhuan, Lichtenberger, Ramtin, Reith, Maike, Tarnanidis, Kathrin, Holland-Letz, Tim, Umansky, Ludmila, Beckhove, Philipp, Sucker, Antje et al. · 2015 · Clinical Cancer Research
11. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
    Hodi, F. Stephen, Ballinger, Marcus, Lyons, Benjamin, Soria, Jean-Charles, Nishino, Mizuki, Tabernero, Josep, Powles, Thomas, Smith, David, Hoos, Axel, McKenna, Chris et al. · 2018 · Journal of Clinical Oncology
12. Moving towards personalized treatments of immune-related adverse events
    Esfahani, Khashayar, Elkrief, Arielle, Calabrese, Cassandra, Lapointe, Réjean, Hudson, Marie, Routy, Bertrand, Miller, Wilson H., Calabrese, Leonard · 2020 · Nature Reviews Clinical Oncology
13. Talimogene laherparepvec: First in class oncolytic virotherapy
    Conry, Robert M., Westbrook, Brian, McKee, Svetlana, Norwood, Timothy Graham · 2018 · Human Vaccines & Immunotherapeutics
14. Targeting programmed cell death -1 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy
    Constantinidou, Anastasia, Alifieris, Constantinos, Trafalis, Dimitrios T. · 2019 · Pharmacology & Therapeutics
15. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects
    Dalvin, Lauren A., Shields, Carol L., Orloff, Marlana, Sato, Takami, Shields, Jerry A. · 2018 · Retina
16. From mice to humans: developments in cancer immunoediting
    Teng, Michele W.L., Galon, Jerome, Fridman, Wolf-Herman, Smyth, Mark J. · 2015 · Journal of Clinical Investigation
17. Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
    Merchant, Melinda S., Wright, Matthew, Baird, Kristin, Wexler, Leonard H., Rodriguez-Galindo, Carlos, Bernstein, Donna, Delbrook, Cindy, Lodish, Maya, Bishop, Rachel, Wolchok, Jedd D. et al. · 2016 · Clinical Cancer Research
18. The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
    Williams, Patrick, Basu, Sreyashi, Garcia‐Manero, Guillermo, Hourigan, Christopher S., Oetjen, Karolyn A., Cortes, Jorge E., Ravandi, Farhad, Jabbour, Elias J., Al‐Hamal, Zainab, Konopleva, Marina et al. · 2019 · Cancer
19. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
    Ravi, Rajani, Noonan, Kimberly A., Pham, Vui, Bedi, Rishi, Zhavoronkov, Alex, Ozerov, Ivan V., Makarev, Eugene, V. Artemov, Artem, Wysocki, Piotr T., Mehra, Ranee et al. · 2018 · Nature Communications
20. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
    Faje, Alexander · 2016 · Pituitary
21. Ipilimumab and Its Toxicities: A Multidisciplinary Approach
    Fecher, Leslie A., Agarwala, Sanjiv S., Hodi, F. Stephen, Weber, Jeffrey S. · 2013 · The Oncologist
22. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
    Eroglu, Zeynep, Ribas, Antoni · 2016 · Therapeutic Advances in Medical Oncology
23. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
    Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A.M.M., Routier, E., Robert, C. · 2013 · Annals of Oncology
24. First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies
    Beatty, Gregory L., O'Dwyer, Peter J., Clark, Jason, Shi, Jack G., Bowman, Kevin J., Scherle, Peggy A., Newton, Robert C., Schaub, Richard, Maleski, Janet, Leopold, Lance et al. · 2017 · Clinical Cancer Research
25. The immune system and cancer evasion strategies: therapeutic concepts
    Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., Hoeller, S. · 2016 · Journal of Internal Medicine
26. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
    Saleh, Reem, Elkord, Eyad · 2020 · Seminars in Cancer Biology
27. Biomineralized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer Therapy
    Qing, Shuang, Lyu, Chengliang, Zhu, Li, Pan, Chao, Wang, Shuang, Li, Feng, Wang, Jianghua, Yue, Hua, Gao, Xiaoyong, Jia, Rongrong et al. · 2020 · Advanced Materials
28. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
    Diem, S, Kasenda, B, Spain, L, Martin-Liberal, J, Marconcini, R, Gore, M, Larkin, J · 2016 · British Journal of Cancer
29. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
    Fan, Xiaozhou, Quezada, Sergio A., Sepulveda, Manuel A., Sharma, Padmanee, Allison, James P. · 2014 · Journal of Experimental Medicine
30. Translational value of mouse models in oncology drug development
    Gould, Stephen E, Junttila, Melissa R, de Sauvage, Frederic J · 2015 · Nature Medicine
31. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis
    Nishijima, Tomohiro F., Muss, Hyman B., Shachar, Shlomit S., Moschos, Stergios J. · 2016 · Cancer Treatment Reviews
32. Interferon-γ links ultraviolet radiation to melanomagenesis in mice
    Zaidi, M. Raza, Davis, Sean, Noonan, Frances P., Graff-Cherry, Cari, Hawley, Teresa S., Walker, Robert L., Feigenbaum, Lionel, Fuchs, Elaine, Lyakh, Lyudmila, Young, Howard A. et al. · 2011 · Nature
33. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
    Abdel-Wahab, Noha, Safa, Houssein, Abudayyeh, Ala, Johnson, Daniel H., Trinh, Van Anh, Zobniw, Chrystia M., Lin, Heather, Wong, Michael K., Abdelrahim, Maen, Gaber, A. Osama et al. · 2019 · Journal for ImmunoTherapy of Cancer
34. The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance
    Fearon, Douglas T. · 2014 · Cancer Immunology Research
35. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients
    Peters, Brandilyn A., Wilson, Melissa, Moran, Una, Pavlick, Anna, Izsak, Allison, Wechter, Todd, Weber, Jeffrey S., Osman, Iman, Ahn, Jiyoung · 2019 · Genome Medicine
36. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
    Kübler, Hubert, Scheel, Birgit, Gnad-Vogt, Ulrike, Miller, Kurt, Schultze-Seemann, Wolfgang, vom Dorp, Frank, Parmiani, Giorgio, Hampel, Christian, Wedel, Steffen, Trojan, Lutz et al. · 2015 · Journal for Immunotherapy of Cancer
37. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
    Karachaliou, Niki, Gonzalez-Cao, Maria, Crespo, Guillermo, Drozdowskyj, Ana, Aldeguer, Erika, Gimenez-Capitan, Ana, Teixido, Cristina, Molina-Vila, Miguel Angel, Viteri, Santiago, De Los Llanos Gil, Maria et al. · 2018 · Therapeutic Advances in Medical Oncology
38. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
    Pauken, Kristen E., Dougan, Michael, Rose, Noel R., Lichtman, Andrew H., Sharpe, Arlene H. · 2019 · Trends in Immunology
39. LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
    Maruhashi, Takumi, Okazaki, Il-mi, Sugiura, Daisuke, Takahashi, Suzuka, Maeda, Takeo K., Shimizu, Kenji, Okazaki, Taku · 2018 · Nature Immunology
40. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
    Delivanis, Danae A, Gustafson, Michael P, Bornschlegl, Svetlana, Merten, Michele M, Kottschade, Lisa, Withers, Sarah, Dietz, Allan B, Ryder, Mabel · 2017 · The Journal of Clinical Endocrinology & Metabolism
41. Therapeutic cancer vaccines: Are we there yet?
    Klebanoff, Christopher A., Acquavella, Nicolas, Yu, Zhiya, Restifo, Nicholas P. · 2011 · Immunological Reviews
42. Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
    Vredevoogd, David W., Kuilman, Thomas, Ligtenberg, Maarten A., Boshuizen, Julia, Stecker, Kelly E., de Bruijn, Beaunelle, Krijgsman, Oscar, Huang, Xinyao, Kenski, Juliana C.N., Lacroix, Ruben et al. · 2019 · Cell
43. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
    Lee, Nayoung, Zakka, Labib R., Mihm, Martin C., Schatton, Tobias · 2016 · Pathology
44. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
    Simeone, Ester, Gentilcore, Giusy, Giannarelli, Diana, Grimaldi, Antonio M., Caracò, Corrado, Curvietto, Marcello, Esposito, Assunta, Paone, Miriam, Palla, Marco, Cavalcanti, Ernesta et al. · 2014 · Cancer Immunology, Immunotherapy
45. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
    Hwang, Sohyun, Kwon, Ah-Young, Jeong, Ju-Yeon, Kim, Sewha, Kang, Haeyoun, Park, Joonsuk, Kim, Joo-Hang, Han, Ok Jin, Lim, Sun Min, An, Hee Jung · 2020 · Scientific Reports
46. Chemoimmunotherapy: Reengineering Tumor Immunity
    Chen, Gang, Emens, Leisha A. · 2013 · Cancer Immunology, Immunotherapy
47. The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy
    Fu, Tihui, He, Qiuming, Sharma, Padmanee · 2011 · Cancer Research
48. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
    Zheng, Xichen, Fang, Zhaoxu, Liu, Xiaomei, Deng, Shengming, Zhou, Pei, Wang, Xuexiang, Zhang, Chenglin, Yin, Rongping, Hu, Haitian, Chen, Xiaolan et al. · 2018 · Journal of Clinical Investigation
49. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
    Ngiow, Shin Foong, Young, Arabella, Jacquelot, Nicolas, Yamazaki, Takahiro, Enot, David, Zitvogel, Laurence, Smyth, Mark J. · 2015 · Cancer Research
50. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
    Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., Routy, B. · 2019 · Annals of Oncology
51. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
    Oh, David Y., Cham, Jason, Zhang, Li, Fong, Grant, Kwek, Serena S., Klinger, Mark, Faham, Malek, Fong, Lawrence · 2017 · Cancer Research
52. The Extrinsic and Intrinsic Roles of PD‐L1 and Its Receptor PD‐1: Implications for Immunotherapy Treatment
    Hudson, Katie, Cross, Neil, Jordan-Mahy, Nicola, Leyland, Rebecca · 2020 · Frontiers in Immunology
53. In vivo discovery of immunotherapy targets in the tumour microenvironment
    Zhou, Penghui, Shaffer, Donald R., Alvarez Arias, Diana A., Nakazaki, Yukoh, Pos, Wouter, Torres, Alexis J., Cremasco, Viviana, Dougan, Stephanie K., Cowley, Glenn S., Elpek, Kutlu et al. · 2014 · Nature
54. Learning from clinical trials of neoadjuvant checkpoint blockade
    Versluis, Judith M., Long, Georgina V., Blank, Christian U. · 2020 · Nature Medicine
55. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
    Iyer, Priyanka C., Cabanillas, Maria E., Waguespack, Steven G., Hu, Mimi I., Thosani, Sonali, Lavis, Victor R., Busaidy, Naifa L., Subudhi, Sumit K., Diab, Adi, Dadu, Ramona · 2018 · Thyroid
56. Comprehensive T cell repertoire characterization of non-small cell lung cancer
    Reuben, Alexandre, Zhang, Jiexin, Chiou, Shin-Heng, Gittelman, Rachel M., Li, Jun, Lee, Won-Chul, Fujimoto, Junya, Behrens, Carmen, Liu, Xiaoke, Wang, Feng et al. · 2020 · Nature Communications
57. Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
    Moslehi, Javid, Lichtman, Andrew H., Sharpe, Arlene H., Galluzzi, Lorenzo, Kitsis, Richard N. · 2021 · Journal of Clinical Investigation
58. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy
    Lines, J. Louise, Sempere, Lorenzo F., Broughton, Thomas, Wang, Li, Noelle, Randolph · 2014 · Cancer Immunology Research
59. <i>Bifidobacterium</i> can mitigate intestinal immunopathology in the context of CTLA-4 blockade
    Wang, Feng, Yin, Qian, Chen, Liang, Davis, Mark M. · 2018 · Proceedings of the National Academy of Sciences
60. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
    Postow, Michael A., Manuel, Manuarii, Wong, Phillip, Yuan, Jianda, Dong, Zhiwan, Liu, Cailian, Perez, Solène, Tanneau, Isabelle, Noel, Marlène, Courtier, Anaïs et al. · 2015 · Journal for ImmunoTherapy of Cancer
61. An RNA toolbox for cancer immunotherapy
    Pastor, Fernando, Berraondo, Pedro, Etxeberria, Iñaki, Frederick, Josh, Sahin, Ugur, Gilboa, Eli, Melero, Ignacio · 2018 · Nature Reviews Drug Discovery
62. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
    Subudhi, Sumit K., Aparicio, Ana, Gao, Jianjun, Zurita, Amado J., Araujo, John C., Logothetis, Christopher J., Tahir, Salahaldin A., Korivi, Brinda R., Slack, Rebecca S., Vence, Luis et al. · 2016 · Proceedings of the National Academy of Sciences
63. Efficacy and Safety of Nivolumab in Patients With <i>BRAF</i> V600 Mutant and <i>BRAF</i> Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials
    Larkin, James, Lao, Christopher D., Urba, Walter J., McDermott, David F., Horak, Christine, Jiang, Joel, Wolchok, Jedd D. · 2015 · JAMA Oncology
64. Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy
    Blake, Stephen J., Dougall, William C., Miles, John J., Teng, Michele W.L., Smyth, Mark J. · 2016 · Clinical Cancer Research
65. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy
    Haanen, J., Ernstoff, M.S., Wang, Y., Menzies, A.M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J.A., Obeid, M. · 2020 · Annals of Oncology
66. Efficacy of PD-1 &amp; PD-L1 inhibitors in older adults: a meta-analysis
    Elias, Rawad, Giobbie-Hurder, Anita, McCleary, Nadine Jackson, Ott, Patrick, Hodi, F. Stephen, Rahma, Osama · 2018 · Journal for ImmunoTherapy of Cancer
67. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors
    Elkrief, Arielle, El Raichani, Layal, Richard, Corentin, Messaoudene, Meriem, Belkaid, Wiam, Malo, Julie, Belanger, Karl, Miller, Wilson, Jamal, Rahima, Letarte, Nathalie et al. · 2019 · OncoImmunology
68. TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts
    Grauel, Angelo L., Nguyen, Beverly, Ruddy, David, Laszewski, Tyler, Schwartz, Stephanie, Chang, Jonathan, Chen, Julie, Piquet, Michelle, Pelletier, Marc, Yan, Zheng et al. · 2020 · Nature Communications
69. The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
    Huff, Wei X., Kwon, Jae Hyun, Henriquez, Mario, Fetcko, Kaleigh, Dey, Mahua · 2019 · International Journal of Molecular Sciences
70. Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
    Amin, Asim, Dudek, Arkadiusz Z, Logan, Theodore F, Lance, Raymond S, Holzbeierlein, Jeffrey M, Knox, Jennifer J, Master, Viraj A, Pal, Sumanta K, Miller, Wilson H, Karsh, Lawrence I et al. · 2015 · Journal for ImmunoTherapy of Cancer
71. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment
    Yang, Li, Li, Aitian, Lei, Qingyang, Zhang, Yi · 2019 · Journal of Hematology &amp; Oncology
72. Hostile, Hypoxia–A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists
    Sitkovsky, Michail V., Hatfield, Stephen, Abbott, Robert, Belikoff, Bryan, Lukashev, Dmitriy, Ohta, Akio · 2014 · Cancer Immunology Research
73. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory
    Kidani, Yujiro, Nogami, Wataru, Yasumizu, Yoshiaki, Kawashima, Atsunari, Tanaka, Atsushi, Sonoda, Yudai, Tona, Yumi, Nashiki, Kunitaka, Matsumoto, Reimi, Hagiwara, Masaki et al. · 2022 · Proceedings of the National Academy of Sciences
74. Engineering patient-specific cancer immunotherapies
    Scheetz, Lindsay, Park, Kyung Soo, Li, Qiao, Lowenstein, Pedro R., Castro, Maria G., Schwendeman, Anna, Moon, James J. · 2019 · Nature Biomedical Engineering
75. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
    Ha, Danbee, Tanaka, Atsushi, Kibayashi, Tatsuya, Tanemura, Atsushi, Sugiyama, Daisuke, Wing, James Badger, Lim, Ee Lyn, Teng, Karen Wei Weng, Adeegbe, Dennis, Newell, Evan W. et al. · 2019 · Proceedings of the National Academy of Sciences
76. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
    Abu-Sbeih, Hamzah, Ali, Faisal S., Luo, Wenyi, Qiao, Wei, Raju, Gottumukkala S., Wang, Yinghong · 2018 · Journal for ImmunoTherapy of Cancer
77. Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
    Lussier, Danielle M, Johnson, John L, Hingorani, Pooja, Blattman, Joseph N · 2015 · Journal for ImmunoTherapy of Cancer
78. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
    Indini, Alice, Di Guardo, Lorenza, Cimminiello, Carolina, Prisciandaro, Michele, Randon, Giovanni, De Braud, Filippo, Del Vecchio, Michele · 2019 · Journal of Cancer Research and Clinical Oncology
79. Clinical Significance of Circulating CD33+CD11b+HLA-DR− Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
    Sade-Feldman, Moshe, Kanterman, Julia, Klieger, Yair, Ish-Shalom, Eliran, Olga, Mizrahi, Saragovi, Amijai, Shtainberg, Hani, Lotem, Michal, Baniyash, Michal · 2016 · Clinical Cancer Research
80. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy
    Ng Tang, Derek, Shen, Yu, Sun, Jingjing, Wen, Sijin, Wolchok, Jedd D., Yuan, Jianda, Allison, James P., Sharma, Padmanee · 2013 · Cancer Immunology Research
81. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
    Koelzer, Viktor H., Rothschild, Sacha I., Zihler, Deborah, Wicki, Andreas, Willi, Berenika, Willi, Niels, Voegeli, Michèle, Cathomas, Gieri, Zippelius, Alfred, Mertz, Kirsten D. · 2016 · Journal for ImmunoTherapy of Cancer
82. Acquired and intrinsic resistance in cancer immunotherapy
    Kelderman, Sander, Schumacher, Ton N.M., Haanen, John B.A.G. · 2014 · Molecular Oncology
83. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma
    Sayour, Elias J., McLendon, Pat, McLendon, Roger, De Leon, Gabriel, Reynolds, Renee, Kresak, Jesse, Sampson, John H., Mitchell, Duane A. · 2015 · Cancer Immunology, Immunotherapy
84. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice
    Kokolus, Kathleen M., Zhang, Ying, Sivik, Jeffrey M., Schmeck, Carla, Zhu, Junjia, Repasky, Elizabeth A., Drabick, Joseph J., Schell, Todd. D. · 2018 · OncoImmunology
85. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
    Reuben, Alexandre, Spencer, Christine N., Prieto, Peter A., Gopalakrishnan, Vancheswaran, Reddy, Sangeetha M., Miller, John P., Mao, Xizeng, De Macedo, Mariana Petaccia, Chen, Jiong, Song, Xingzhi et al. · 2017 · npj Genomic Medicine
86. The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment
    Hendry, Shona A., Farnsworth, Rae H., Solomon, Benjamin, Achen, Marc G., Stacker, Steven A., Fox, Stephen B. · 2016 · Frontiers in Immunology
87. Engineered skin bacteria induce antitumor T cell responses against melanoma
    Chen, Y. Erin, Bousbaine, Djenet, Veinbachs, Alessandra, Atabakhsh, Katayoon, Dimas, Alex, Yu, Victor K., Zhao, Aishan, Enright, Nora J., Nagashima, Kazuki, Belkaid, Yasmine et al. · 2023 · Science
88. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
    Morganstein, D.L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., Larkin, J. · 2017 · Clinical Endocrinology
89. Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies
    Chen, Jonathan H., Pezhouh, Maryam K., Lauwers, Gregory Y., Masia, Ricard · 2017 · American Journal of Surgical Pathology
90. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka B., Dong, Zhiwan, Gusenleitner, Daniel, Giobbie-Hurder, Anita, Severgnini, Mariano, Zhou, Jun, Manos, Michael, Eastman, Lauren M., Maecker, Holden T., Hodi, F. Stephen · 2018 · Journal for ImmunoTherapy of Cancer
91. Targeted antibody and cytokine cancer immunotherapies through collagen affinity
    Ishihara, Jun, Ishihara, Ako, Sasaki, Koichi, Lee, Steve Seung-Young, Williford, John-Michael, Yasui, Mariko, Abe, Hiroyuki, Potin, Lambert, Hosseinchi, Peyman, Fukunaga, Kazuto et al. · 2019 · Science Translational Medicine
92. Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609
    Tarhini, Ahmad A., Lee, Sandra J., Hodi, F. Stephen, Rao, Uma N. M., Cohen, Gary I., Hamid, Omid, Hutchins, Laura F., Sosman, Jeffrey A., Kluger, Harriett M., Eroglu, Zeynep et al. · 2020 · Journal of Clinical Oncology
93. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors
    Lidar, Merav, Giat, Eitan, Garelick, Daniela, Horowitz, Yuval, Amital, Howard, Steinberg-Silman, Yael, Schachter, Jacob, Shapira-Frommer, Ronnie, Markel, Gal · 2018 · Autoimmunity Reviews
94. The promising immune checkpoint LAG‐3 in cancer immunotherapy: from basic research to clinical application
    Huo, Jin-Ling, Wang, Ya-Tao, Fu, Wen-Jia, Lu, Nan, Liu, Zhang-Suo · 2022 · Frontiers in Immunology
95. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
    Fumet, Jean-David, Richard, Corentin, Ledys, Fanny, Klopfenstein, Quentin, Joubert, Philippe, Routy, Bertrand, Truntzer, Caroline, Gagné, Andréanne, Hamel, Marc-André, Guimaraes, Camila Figueiredo et al. · 2018 · British Journal of Cancer
96. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
    Martens, Alexander, Wistuba-Hamprecht, Kilian, Yuan, Jianda, Postow, Michael A., Wong, Phillip, Capone, Mariaelena, Madonna, Gabriele, Khammari, Amir, Schilling, Bastian, Sucker, Antje et al. · 2016 · Clinical Cancer Research
97. Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study
    Bajwa, Ravneet, Cheema, Anmol, Khan, Taimoor, Amirpour, Alireza, Paul, Anju, Chaughtai, Saira, Patel, Shrinil, Patel, Tejas, Bramson, Joshua, Gupta, Varsha et al. · 2019 · Journal of Clinical Medicine Research
98. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
    Hinterleitner, Clemens, Strähle, Jasmin, Malenke, Elke, Hinterleitner, Martina, Henning, Melanie, Seehawer, Marco, Bilich, Tatjana, Heitmann, Jonas, Lutz, Martina, Mattern, Sven et al. · 2021 · Nature Communications
99. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
    Min, Le, Vaidya, Anand, Becker, Carolyn · 2011 · European Journal of Endocrinology
100. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
     Yamauchi, Ichiro, Sakane, Yoriko, Fukuda, Yorihide, Fujii, Toshihito, Taura, Daisuke, Hirata, Masakazu, Hirota, Keisho, Ueda, Yohei, Kanai, Yugo, Yamashita, Yui et al. · 2017 · Thyroid